16:07 EDT Tvardi Therapeutics (TVRD) files $200M mixed securities shelf
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
- Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
- Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
- Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
- Tvardi Therapeutics price target lowered to $4 from $5 at Barclays